BioMosaics is a leading provider of diagnostic immunohistochemistry products.
We commercialize biomarker assays and reagents for the early detection of cancer, for use in clinical and research settings. We take pride in providing you with products that are reliable and consistent; products you can depend on. Our product and service focus: primary antibodies for IHC with clinical utility for the diagnosis of cancer select immunoassays with promise for oncologic areas of unmet need biomarkers of somatic mutation and genetic damage.
Our product and service focus:
- Primary antibodies for IHC with clinical utility for the diagnosis of cancer
- Select immunoassays with promise for oncologic areas of unmet need
- Biomarkers of somatic mutation and genetic damage
- Biomarker contract service testing for biotech/pharma
Imaging hepatocellular carcinoma using 89Zr-labeled anti-glypican-3 monoclonal antibody.
Immuno-PET, the tracking and quantification of monoclonal antibodies using positron emission tomography (PET) cameras, is an exciting innovation to increase the ability to detect cancer. Immuno-PET has recently reached maturity in terms of technical development and is now entering the phase of broad-scale clinical application. We are currently developing our 89Zr-labeled anti-glypican-3 monoclonal antibody as a diagnostic imaging agent for hepatocellular carcinoma through a collaboration with Stanford University.